MeSH D003930 - diabetic retinopathy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Faricimab | Vabysmo |  | 2022-09-15 | $2,221.9 M | Q4/22-Q3/23 |
| Novartis | Ranibizumab | Lucentis |  | 2007-01-22 | $1,848 M | Q2/20-Q2/23 |
| Sanofi | Aflibercept | Zaltrap |  | 2012-08-03 |  |  |
| Bayer | Aflibercept | Eylea |  | 2012-11-21 |  |  |
| Genentech | Ranibizumab | Lucentis |  | 2006-06-30 |  |  |
| Ranibizumab | Susvimo |  | 2021-10-22 |  |  | |
| Faricimab | Vabysmo |  | 2022-01-28 |  |  | |
| Stada Arzneimittel | Ranibizumab | Ximluci |  | 2022-11-09 |  |  |
| Samsung Bioepis | Ranibizumab | Byooviz |  | 2021-09-17 |  |  |
| Midas Pharma | Ranibizumab | Ranivisio |  | 2022-08-25 |  |  |
| Regeneron Pharmaceuticals | Aflibercept | Eylea |  | 2011-11-18 | $5,487.4 M | Q2/23-Q1/24 |
| Coherus BioSciences | Ranibizumab | Cimerli |  | 2022-08-02 | $147.408 M | Q2/23-Q1/24 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%12/24
Phase 2
50%17/34
Phase 3
44%14/32
Approved: 5Overall Success rate: 11%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use